AgomAb Therapeutics NV (AGMB) vs Entera Bio (ENTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Entera Bio is the larger company by market cap ($436.3 million vs $433.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | ENTX |
|---|---|---|
| Share price | $8.80 | $2.51 |
| Market cap | $433.38M | $436.32M |
| 1-day change | -0.45% | -0.79% |
| YTD return | — | +29.38% |
| 1-year return | — | +32.80% |
| 5-year return | — | -44.47% |
| EPS (TTM) | $-2.08 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $4.20 |
| 52-week low | $7.97 | $0.91 |
| Distance from 52-week high | -50.62% | -40.24% |
| Average volume | 135.61K | 1.81M |
| Shares outstanding | 49.25M | 173.83M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
AGMB vs ENTX FAQ
Which is bigger, AgomAb Therapeutics NV or Entera Bio?
Entera Bio (ENTX) is larger, with a market capitalization of $436.32M compared with $433.38M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and Entera Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.